Hunter Perkins Capital Management LLC Has $24.11 Million Stock Position in Labcorp Holdings Inc. $LH

Hunter Perkins Capital Management LLC decreased its holdings in Labcorp Holdings Inc. (NYSE:LH) by 8.1% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 96,106 shares of the medical research company’s stock after selling 8,488 shares during the quarter. Labcorp accounts for approximately 5.6% of Hunter Perkins Capital Management LLC’s holdings, making the stock its 2nd biggest position. Hunter Perkins Capital Management LLC owned approximately 0.12% of Labcorp worth $24,111,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in the stock. Dakota Wealth Management raised its stake in Labcorp by 98.6% during the 3rd quarter. Dakota Wealth Management now owns 10,303 shares of the medical research company’s stock valued at $2,958,000 after buying an additional 5,116 shares during the last quarter. Independent Advisor Alliance boosted its stake in shares of Labcorp by 166.6% in the 3rd quarter. Independent Advisor Alliance now owns 12,111 shares of the medical research company’s stock worth $3,477,000 after buying an additional 7,568 shares during the last quarter. New York State Common Retirement Fund boosted its stake in shares of Labcorp by 12.0% in the 3rd quarter. New York State Common Retirement Fund now owns 44,795 shares of the medical research company’s stock worth $12,859,000 after buying an additional 4,800 shares during the last quarter. Lazard Asset Management LLC grew its holdings in shares of Labcorp by 224.1% in the second quarter. Lazard Asset Management LLC now owns 989,433 shares of the medical research company’s stock worth $259,734,000 after acquiring an additional 684,153 shares during the period. Finally, Franklin Resources Inc. grew its holdings in shares of Labcorp by 3.1% in the second quarter. Franklin Resources Inc. now owns 34,331 shares of the medical research company’s stock worth $9,012,000 after acquiring an additional 1,043 shares during the period. Hedge funds and other institutional investors own 95.94% of the company’s stock.

Labcorp Price Performance

NYSE LH opened at $264.52 on Friday. The business’s fifty day moving average is $274.20 and its 200 day moving average is $269.17. Labcorp Holdings Inc. has a fifty-two week low of $209.38 and a fifty-two week high of $293.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42. The company has a market capitalization of $21.80 billion, a PE ratio of 25.29, a price-to-earnings-growth ratio of 1.80 and a beta of 1.01.

Labcorp (NYSE:LH) last issued its quarterly earnings results on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, topping analysts’ consensus estimates of $3.95 by $0.12. Labcorp had a return on equity of 16.16% and a net margin of 6.28%.The business had revenue of $3.52 billion during the quarter, compared to analysts’ expectations of $3.56 billion. During the same quarter in the prior year, the business posted $3.45 earnings per share. The business’s quarterly revenue was up 5.6% on a year-over-year basis. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. Sell-side analysts predict that Labcorp Holdings Inc. will post 16.01 earnings per share for the current year.

Labcorp Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Thursday, March 12th. Shareholders of record on Friday, February 27th were paid a dividend of $0.72 per share. The ex-dividend date was Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.1%. Labcorp’s dividend payout ratio (DPR) is presently 27.53%.

Analyst Upgrades and Downgrades

LH has been the topic of a number of recent research reports. Robert W. Baird increased their target price on Labcorp from $313.00 to $326.00 and gave the company an “outperform” rating in a report on Wednesday, February 18th. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Piper Sandler upped their price target on shares of Labcorp from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, February 24th. Weiss Ratings upgraded shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Tuesday, February 10th. Finally, JPMorgan Chase & Co. boosted their target price on shares of Labcorp from $319.00 to $330.00 and gave the company an “overweight” rating in a research report on Wednesday, February 18th. Nine analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, Labcorp presently has an average rating of “Moderate Buy” and a consensus price target of $304.82.

Insider Activity

In other news, CEO Adam H. Schechter sold 8,705 shares of the stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $279.96, for a total value of $2,437,051.80. Following the completion of the sale, the chief executive officer directly owned 80,773 shares of the company’s stock, valued at $22,613,209.08. This represents a 9.73% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Brian J. Caveney sold 1,500 shares of the firm’s stock in a transaction on Tuesday, February 24th. The shares were sold at an average price of $286.31, for a total transaction of $429,465.00. Following the sale, the executive vice president owned 30,107 shares in the company, valued at $8,619,935.17. The trade was a 4.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 16,113 shares of company stock worth $4,547,450 over the last ninety days. Company insiders own 0.84% of the company’s stock.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.